White Paper

Understanding The New FDA DHT Guidance

Source: ActiGraph
GettyImages-1139719728 FDA

The FDA released its first guidance specific to the use of digital health technologies (DHT) in December 2021. This is an important milestone signifying the willingness from the regulators to adopt new digital clinical measurements, especially for remote data collection.

To help sponsors, particularly those new to DHTs, we have developed this practical guide to facilitate the use of DHTs and maximize their benefits to clinical investigations. This guide is focused on sensor-based DHTs, specifically study dedicated, research-grade wearable devices. This discussion does not cover questionnaire-based DHTs or BYOD models.

The FDA encourages sponsors to engage early with the relevant review divisions and/or the qualification programs to discuss the use of DHTs and to leverage existing data and expertise made available by the DHT manufacturer.

VIEW THE WHITE PAPER!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Clinical Leader